Literature DB >> 10094952

Down-regulation of insulin-like growth factor binding proteins and growth modulation in hepatoma cells by retinoic acid.

D G Kim1, D Y Lee, B H Cho, K R You, M Y Kim, D S Ahn.   

Abstract

We observed that all-trans-retinoic acid (RA) down-regulated insulin-like growth factor binding proteins (IGFBPs) in cultured human hepatoma cells (Hep 3B, PLC/PRF/5, and Hep G2); therefore, we characterized the role of this down-regulation in cell growth. Treatment with 10 micromol/L RA revealed a rapid decrease in IGFBP-3 within 2 days, and continued treatment with RA for 6 days resulted in a time-dependent stimulation of Hep 3B cell growth. However, RA treatment decreased IGFBP-1 in PLC/PRF/5 cells and in Hep G2 cells, and the growth-stimulatory activity of RA was transient and less prominent, and was finally obliterated in both cell lines. The addition of 5 ng/mL or 50 ng/mL insulin-like growth factors (IGFs) did not change the growth effects elicited by RA. The addition of IGFBP-3 (1,000 ng/mL) inhibited the growth of Hep 3B cells and counteracted the growth-stimulatory activity of RA, but not completely, suggesting that RA has direct growth-stimulatory activity and that this is enhanced by autocrine down-regulation of IGFBP-3. IGFBP-3 also inhibited the growth of PLC/PRF/5 cells and of Hep G2 cells. Treatment with phosphorylated IGFBP-1 (1,000 ng/mL) alone or with RA did not affect the growth of PLC/PRF/5 cells or Hep G2 cells. However, addition of dephosphorylated IGFBP-1, derived from in vivo dephosphorylation of the phosphorylated form, stimulated the growth of both cell lines, independent of interaction with IGF-I. From these observations, we propose that RA down-regulates IGFBPs, which in turn causes autocrine modulation of cell growth independent of IGF in hepatoma cells in vitro or in vivo. In addition, RA regulates IGFBPs at the posttranscriptional (Hep 3B cells and Hep G2 cells) or transcriptional level (PLC/PRF/5 cells) in a cell-specific manner.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094952     DOI: 10.1002/hep.510290414

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

Review 1.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

2.  Impaired hepatocyte DNA synthetic response posthepatectomy in insulin-like growth factor binding protein 1-deficient mice with defects in C/EBP beta and mitogen-activated protein kinase/extracellular signal-regulated kinase regulation.

Authors:  Julia I Leu; Mary Ann S Crissey; Linden E Craig; Rebecca Taub
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

Review 3.  Intestinal hormones and growth factors: effects on the small intestine.

Authors:  Laurie Drozdowski; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2009-01-28       Impact factor: 5.742

Review 4.  Targeting insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Jennifer Wu; Andrew X Zhu
Journal:  J Hematol Oncol       Date:  2011-07-05       Impact factor: 17.388

5.  Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation.

Authors:  Tadashi Hanafusa; Toshiyuki Shinji; Hidenori Shiraha; Kazuhiro Nouso; Yoshiaki Iwasaki; Eichiro Yumoto; Toshiro Ono; Norio Koide
Journal:  BMC Cancer       Date:  2005-01-20       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.